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Abstract
Background—Timeliness of care may contribute to racial disparities in breast cancer mortality.
African American women experience greater treatment delay than White women in most, but not
all studies. Understanding these disparities is challenging since many studies lack patient-reported
data and use administrative data sources that collect limited types of information. We used
interview and medical record data from the Carolina Breast Cancer Study (CBCS) to identify
determinants of delay and assess whether disparities exist between White and African American
women (n=601).
Methods—The CBCS is a population-based study of North Carolina women. We investigated
the association of demographic and socioeconomic characteristics, healthcare access, clinical
factors, and measures of emotional and functional well-being with treatment delay. The
association of race and selected characteristics with delays of >30 days were assessed using
logistic regression.
Results—Household size, losing a job due to one’s diagnosis, and immediate reconstruction
were associated with delay in the overall population and among White women. Immediate
reconstruction and treatment type were associated with delay among African American women.
Racial disparities in treatment delay were not evident in the overall population. In the adjusted
models, African American women experienced greater delay than White women for younger age
groups: odds ratio (OR), 3.34; 95% confidence interval (CI), 1.07–10.38 for ages 20–39, and OR,
3.40; 95% CI, 1.76–6.54 for ages 40–49.
Conclusions—Determinants of treatment delay vary by race. Racial disparities in treatment
delay exist among women <50 years old.
Impact—Specific populations need to be targeted when identifying and addressing determinants
of treatment delay.
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African American women have a higher breast cancer mortality compared to White women,
even after accounting for clinical and prognostic factors(1–4) and socioeconomic
characteristics(5). Timeliness has been used as an indicator of quality of care (6, 7) and may
contribute in part to these persistent disparities. African American women demonstrate
greater delays in care than White women at multiple points along the treatment pathway
from detection to medical consultation/diagnosis ("diagnostic delay")(7–12) and from
diagnosis to the initiation of treatment (“treatment delay”)(7–9, 13–17). Although the
majority of studies demonstrate that African American women are more likely than White
women to experience treatment delay (8, 14, 15, 17–20), not all studies find differences
between these groups (21–23).
The impact of socioeconomic characteristics has been heavily investigated, but does not
fully explain racial disparities in timeliness of care. A study on Medicare beneficiaries found
that African American women were more likely than White women to experience delays
between initial consultation (a diagnostic imaging procedure or consultation for symptoms)
and diagnosis, as well as between diagnosis and treatment(9). In a Washington, D.C. cohort,
African American women were more likely than White women to experience delay between
the identification of a suspicious finding and diagnostic resolution even among women with
the same type of insurance coverage (private or government)(10). Even among low-income,
uninsured women enrolled in the National Breast and Cervical Cancer Early Detection
Program (NBCCEDP), African American women are more likely to experience diagnostic
delay and treatment delay(7).
Limitations in the assessment of socioeconomic characteristics may affect the validity and
interpretation of the results for many studies performed to date. First, detailed
socioeconomic data is often unavailable in investigations with large study populations(24).
Area-level data (e.g. census tracts, zip codes) are used as a proxy for individual-level income
and education (8, 9, 15, 25–29). These measures may be unreliable when there is marked
heterogeneity within the area being analyzed(30). Additionally, they may not adequately
control for confounding since studies suggest that area-level and individual-level
characteristics independently impact breast cancer outcomes(31, 32). Second, studies often
combine persons with Medicare and Medicaid coverage into a single category (10, 13, 14).
Results for this heterogeneous category are difficult to interpret, particularly given the
marked distinctions in breast cancer outcomes for these groups(15, 16, 33).
Identifying additional determinants of treatment delay will improve our understanding of
racial disparities and is critical for developing interventions and policy to ensure timely care.
Investigations based solely on administrative, cancer registry, or medical record data are
fairly limited in the types of information they collect and thus are less amenable to
discovering novel determinants of delay(7, 28). The goals of this study were to identify
determinants of breast cancer treatment delay and to determine whether disparities in
treatment delay exist between White and African American women. We use data from a
population-based study to assess the association of demographic and socioeconomic
characteristics, indicators of healthcare access, clinical factors, and measures of emotional
and functional well-being with treatment delay. By combining medical record and patient-
reported data, we were able to assess several factors that are not typically evaluated in other
investigations and to obtain individual-level socioeconomic data.
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The Carolina Breast Cancer Study (CBCS) phase III is an ongoing population-based study
of breast cancer in North Carolina. The design is similar to earlier phases (34, 35), except
that it is a case-only study and has a larger recruitment area (44 counties). Eligible
participants are 1) 20–74 years old, 2) North Carolina residents at the time of diagnosis, and
3) have incident, pathologically-confirmed invasive primary breast cancer. Women with a
previous diagnosis of invasive breast cancer are excluded. A random sample of eligible
women is selected from the following strata: 1) African Americans <50 years old, 2) African
Americans ≥50 years old, 3) non-African Americans <50 years old, and 4) non-African
Americans ≥50 years old. The sampling fractions are 100%, 60%, 40%, and 15%,
respectively. At baseline participants are interviewed by a nurse, complete a quality-of-life
questionnaire, and provide written consent for medical record requests.
The present study uses abstracted medical record data and baseline nurse-administered
interview and questionnaire data for women diagnosed between May 1, 2008 and January
29, 2010 (N=771). Participants were non-Hispanic White (“White”) or non-Hispanic
African American (“African American”), received either surgery or neoadjuvant
chemotherapy and/or hormone therapy (“neoadjuvant therapy”) as their first course of
treatment, had a known treatment date, and were diagnosed based on a core needle biopsy
(CNB) prior to treatment. Participants who received pre-operative chemotherapy or
hormonal therapy, or pre- and post-operative chemotherapy or hormone therapy were
classified as having received neoadjuvant therapy as their first course of treatment.
Hispanics and other racial groups were not analyzed due to small numbers (<3% for both).
The final study population consisted of 601 women (Figure 1). This study was approved by
the Office of Human Research Ethics at the University of North Carolina at Chapel Hill.
Study variables
The main exposure, race, was obtained from self-report. We calculated treatment delay
(main outcome) as the time in days between the date of the CNB used to diagnose invasive
disease and the initiation of the first course of treatment. Treatment delay was dichotomized
as >30 days (“delay”) or ≤30 days. Although this is a commonly used threshold (7, 9, 16,
17), the clinically relevant delay for first course of treatment is unknown. Additional details
on the study variables are provided in Supplementary Material 1.
Statistical Analysis
The percentages shown in Tables 1–2 were weighted to obtain North Carolina population
estimates (hereafter referred to as the “overall population”). The sample sizes shown in the
tables are unweighted. The study design was accounted for in tests of associations between
categorical variables. Logistic regression was used to estimate the odds ratios (ORs) and
95% confidence interval (95% CIs) for the association between each exposure and delay.
Separate models were developed for each exposure (race and characteristics of delay
identified in bivariate analyses) to account for the different sets of explanatory variables
necessary to control for confounding (36, 37). Based on the literature, the following
explanatory variables were included in the adjusted models to estimate the direct effect of
race (White or African American) on delay: age (20–39, 40–49, 50–64, 65–74); income (≤
$20,000, $20,000-$30,000, >$30,000); insurance coverage (private, Medicare, Medicaid,
none); education (0–12 years, but no high school degree; high school graduate; some
college; technical or business school; college degree or higher); lost a job due to one’s
diagnosis (yes or no); American Joint Committee on Cancer (AJCC) disease stage (I, IIA,
IIB, III/IV); symptoms (yes or no); first treatment/reconstruction (breast conserving surgery
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[BCS], mastectomy without reconstruction, mastectomy with reconstruction, neoadjuvant
therapy); and marital status (married, unmarried). We estimated the total effect of the
following characteristics on delay: the number of people supported by the household income
("household size"; explanatory variables: age, race, marital status), losing a job due to one's
diagnosis (explanatory variables: age, race, education), and first treatment/reconstruction
(explanatory variables: age, race, education, income, insurance, education, disease stage).
All variables were treated as categorical. An interaction term between age and race was
included in all models to account for the study design. The study population rather than the
overall population was used in the models to ensure a sufficient number of women of both
races for each age group. All P values were two-sided and P < 0.05 was considered
statistically significant. Statistical analyses were performed using SAS 9.2 (SAS Institute
Inc., Cary, North Carolina).
Results
Population characteristics
The contact rate for the study (number of women selected for the study - number of women
who could not be located or did not respond) was 95.4%. The cooperation rate (number of
women who completed interviews/number of women contacted and eligible) was 80.2%.
The overall response rate (number of completed interviews/[number of women selected -
number ineligible or deceased]) (38) was 75.9%. The median time elapsed between
diagnosis and the baseline interview was 5.1 months (interquartile range [IQR] = 4.0–6.2
months). The median time from diagnosis until treatment was 27.0 days (IQR = 18.0–37.0
days) for the study population and 26.2 days (IQR = 16.3–36.1 days) for the overall
population. The majority (84.2%) of women in the overall population had a CNB prior to
treatment. There was no association between receipt of a CNB and race (P = 0.39) in the
overall population (or study population). There was a significant association between receipt
of a CNB and income (P = 0.047) in the overall population: 93.3% of women with an
income of >$100,000 had a CNB versus 79.2%–81.6% of women with lower incomes.
As shown in Table 1, delay was significantly associated with household size (P = 0.011),
losing a job due to one's diagnosis (P < 0.01), and immediate reconstruction after
mastectomy (P < 0.01). Women with smaller households were more likely than women with
larger households to experience delay: 35.2%–47.3% for households of ≤ 3 people versus
<30% for households of >3 people. Women who lost a job due to their diagnosis and who
underwent immediate reconstruction were nearly twice as likely to experience delay
compared to women who did not (73.6% versus 37.8%, and 64.9% versus 35.6%,
respectively). The prevalence of women in the overall population with households of ≤ 3
people, who lost a job due to their diagnosis, and who underwent immediate reconstruction
was 17.0%, 3.5%, and 10.6%, respectively. The latter value is the product of the immediate
reconstruction and mastectomy rates. African American women were slightly more likely
than White women to experience delay (43.4% versus 38.4%; P = 0.24). None of the other
characteristics were significantly associated with delay.
Few women experienced a delay of >60 days (2.6%; data not shown). Race was strongly
associated with delays of this length, with African American women being more than three
times as likely as White women to experience delay (6.0% versus 1.7%; P = 0.013). For
most categories, less than 5% of women experienced a delay of >60 days. Women in the
following categories were exceptions: underwent immediate reconstruction (12.9%), were
unable to see a doctor in the past 10 years due to a lack of transportation (9.3%), completed
technical or business school (6.3%), underwent mastectomy (6.1%), had not accepted their
illness at all (6.1%), had Medicaid coverage (5.5%), and had a household of 4 people
(5.3%).
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Race, population characteristics, and breast cancer treatment delay
African American women differed markedly from White women for nearly every
demographic and socioeconomic characteristic, measure of healthcare access, and clinical
factor (Table 2). The following characteristics were exceptions: working since diagnosis (P
= 0.69), family history (P = 0.35), first course of treatment (P = 0.46), and immediate
reconstruction (P = 0.079). Race was not associated with the measures of emotional and
functional well-being: P = 0.67 and P = 0.26 for the degree of satisfaction with their coping
and acceptance of their illness, respectively. Among the characteristics associated with
delay, African American women were more than twice as likely as White women to lose a
job due to their diagnosis (6.6% versus 2.7%), slightly more likely to have a household of ≤
3 people, (84.6% versus 82.5%), and less likely to undergo immediate reconstruction (25.2%
versus 37.9%).
The stratified data (Table 2) revealed that the determinants of delay are not equivalent for
White and African American women. The only determinant common to both groups was
immediate reconstruction (P < 0.01 for each group). Household size and losing a job due to
one’s diagnosis were significantly associated with delay among White women (P = 0.027
and P < 0.01, respectively), while the first course of treatment was significantly associated
with delay among African American women (P < 0.01).
While race was not associated with delay in the aggregated data, the stratified data revealed
racial disparities for women with similar characteristics (e.g. same educational level).
African American women were more likely than White women to experience delay for most
characteristics. For instance, 55.6% of African American women with stage IIB disease
experienced delay versus 36.5% of White women with stage IIB disease. The frequency of
delay for African American women exceeded the frequency for White women by >30% for
the following categories: detection by a method other than a routine mammogram, clinical
breast exam, or self-or spouse-detection (70.0% for African American women versus 33.3%
for White women), no insurance coverage (48.9% for African American women versus
15.3% for White women), households of 4 people (53.5% for African American women
versus 23.2% for White women), and undergoing immediate reconstruction (92.5% for
African American women versus 60.6% for White women).
Losing a job due to one’s diagnosis was associated with the highest probability of delay
among White women. It was also the only characteristic in which the frequency of delay
among White women was >30% higher than for African American women: 87.2% versus
52.6%. Having no insurance coverage was associated with the lowest probability of delay
among White women (15.3%). Age (P = 0.067) and symptoms (P = 0.051) also showed
evidence of an association with delay among White women. Women ages 50–64 and
without symptoms tended to be more likely to experience delays. Undergoing immediate
reconstruction was associated with the highest probability of delay among African American
women, while having less than a high school degree was associated with the lowest
probability of delay (26.4%). Income (P = 0.090) showed evidence of an association with
delay among African American women, but there was no clear trend among categories.
Association of selected study population characteristics with delay
In the fully adjusted models, women with 2-person households were more likely than single
person households to experience delay (OR, 2.08; 95% CI, 1.19–3.63) (Table 3). The
probability of delay decreased with increasing household size for households of ≥2 people.
Women who lost a job due to their diagnosis were more likely to experience delay compared
to women who did not (OR, 2.19; 95% CI, 1.00–4.81), although the result was not
significant (P = 0.050). Women who underwent mastectomy with immediate reconstruction
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(OR, 6.18; 95% CI, 3.27–11.68) and neoadjuvant therapy (OR, 2.06; 95% CI, 1.16–3.66)
were more likely than women who received BCS to experience delay.
Association of race with delay for the study population
Racial disparities in delay were significant among women <50 years old (Table 4). The
disparity was largely explained by the low likelihood of delay among younger White
women. African American women were more than three times as likely as White women to
experience delay among women 20–39 years old (OR, 3.34; 95% CI, 1.07–10.38) and 40–49
years old (OR, 3.40; 95% CI, 1.76–6.54). Among White women, delays were less likely for
20–39 year old and 40–49 year old women (OR, 0.32; 95% CI, 0.13–0.80 and OR, 0.38;
95% CI, 0.20–0.73, respectively) relative to women 50–64 years old. The likelihood of
delay for African American women did not differ significantly based on age.
Discussion
This study found that African American women were more likely than White women to
experience delay among younger age groups (<50 years), but not among older age groups.
This disparity was not evident in the overall population, as we found no association between
race and delay in the aggregated data. Household size, losing a job due to one’s diagnosis,
and immediate reconstruction were associated with delay in the overall population and
among White women, respectively. Among African American women, who were a minority
in the overall population, immediate reconstruction and first course of treatment were
associated with delay. The adjusted models demonstrated that women with 2-person
households experienced greater delay than women with other household sizes and women
who had mastectomy with immediate reconstruction experienced greater delay than women
who received other treatments.
It is unclear why a smaller household size was associated with delay. Further investigation is
needed to understand this finding. Increased delay among women who lose a job due to their
diagnosis may be related to a loss of employer-based insurance coverage, greater financial
constraints, or an unsupportive work environment. We are unaware of any quantitative
studies of treatment delay that evaluate employment changes. Losing a job may impact
delay only among White women because they are more likely to have private coverage(1,
29, 39, 40). African American women were more likely than White women to lose a job due
even though the frequency of working since one's diagnosis was comparable for both racial
groups. This result is in agreement with a study that found that African American women
were more likely than White women, to stop working (OR, 3.0; 95% CI, 1.3–6.7) or miss
work for >1month (OR, 3.0; 95% CI, 1.2–7.4), respectively, compared to missing work for ≤
1 month(41). African American women are also less likely than White women to be
employed 18 months following diagnosis (OR, 0.35; 95% CI, 0.18–0.68)(42).
The additional time necessary for consultation and coordination of the schedules of the
plastic surgeon and primary surgeon may explain the increased delay associated with
immediate reconstruction. This is not the first study to report increased delay associated with
this procedure(19, 43), but most studies on treatment delay do not consider this factor.
Immediate reconstruction was the only factor associated with delay for both racial groups.
African American women were less likely than White women to undergo immediate
reconstruction, but more likely to experience delays if they underwent this procedure.
Although not significant, our finding that African American women are less likely to
undergo immediate reconstruction has been observed in several studies(44–46). First course
of treatment was associated with delay only among African American women and was not
explained by differences in the types of treatment received. African American and White
women may differ in this determinant because they receive care at different types of
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healthcare facilities as a result of insurance status and income(16, 47, 48), residential
segregation(49, 50), and urban/rural residence(48). Healthcare facility characteristics are
known to affect treatment delay(15, 17). Immediate reconstruction rates also vary based on
the healthcare facility (51).
It is challenging to compare the frequency of treatment delay across studies due to variations
in study design, recruitment criteria, and study population characteristics. The start point of
the treatment delay period has been defined in various ways, including the date of first
clinical confirmation (15, 23), a suspicious finding (15), and pathological diagnosis (7).
Eligibility restrictions based on disease stage (15, 21, 43) and type of treatment received
(e.g. one type (16, 43, 52) versus all types (14, 47)) also limit comparability. Recruitment of
women from a specific healthcare facility or set of facilities (e.g. single versus multiple,
public/public safety net versus private)(16, 23, 53) and a specific program(22, 52) may lead
to marked differences in population characteristics. The frequency of delay (>30 days)
reported in the literature (7–9, 14–18, 52) ranges from 21.8% (7) to 68.9% (16). Our result
(39.4%) is similar to the results from two different national studies (15, 17) that obtained
values of 34.9% and 42.6%, respectively.
The frequency of delay reported in the literature for African American and White women
(7–9, 14, 16–18) ranges from 18.7% (14) to 70.8% (16) and 4.7% (14) to 56.1% (16),
respectively. Our results (43.3% and 38.4% for African American and White women,
respectively) are fairly similar to those from a national study that reported values of 53.0%
and 40.4%, respectively (17). Delays of >60 days were uncommon in this population, but
are more frequent in studies focusing on women who are uninsured, have Medicaid
coverage, or have low incomes(23, 54). Our finding that African American women are more
likely to experience a delay of >60 days is consistent with other studies(17, 18). Since the
determinants of delay identified in bivariate analysis are highly dependent on the
predominant study population characteristics, this may explain the conflicting literature on
racial disparities in treatment delay. Studies that do not report an association between race
and delay tend to restrict the study population based on socioeconomic characteristics,
disease stage, or the healthcare facility at which they receive care(21–23, 52). Differences in
the determinants of treatment delay and racial disparities in delay are likely diminished for
more homogeneous populations.
The findings of this study suggest the need to focus on well-defined populations when using
treatment delay to make comparisons between groups, monitor changes over time, or assess
quality of care. Interpreting this measure is not straightforward since it is affected by many
factors, including disease stage (15), education (14), poverty index (14), urban/rural
residence (9), marital status (14, 16), comorbidities (14, 15, 17), signs/symptoms at
presentation (55), mammography history (14), hospital type(15–17, 47), whether diagnosis
and treatment occur at the same or different hospitals (15), and year of diagnosis(15, 17).
Treatment delay has been used to evaluate the quality of the NBCCEDP and the impact of
policy changes(56). Although 94% of women meet their target of initiating treatment ≤60
days after diagnosis, racial disparities exist and could be related to programmatic differences
and geographic distinctions among other factors(7, 56). Therefore, interpreting and
addressing this disparity is challenging even though participants share many characteristics
and follow similar treatment guidelines.
Our findings also suggest that developing effective interventions for treatment delay require
studies targeting specific populations. The impact of treatment delay on survival has been
investigated in highly selected populations, including women in a program targeting
underserved populations (22), with Medicaid coverage(54), with triple negative breast
cancer(57), receiving care at two hospitals served by the same providers following identical
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clinical protocols (47), and with metastatic disease (21). The results may not be
generalizable, but these studies are helpful for identifying specific populations who may
experience negative outcomes and the clinically relevant delay period. For instance, a study
of Medicaid recipients in North Carolina found that a treatment delay of ≥60 days was
associated with higher breast cancer–specific mortality among women with late stage
disease (hazard ratio, 1.85; 95% CI, 1.04–3.27), but not among women with early stage
disease(54). Characterizing and addressing the determinants of delay for this specific
subgroup of Medicaid recipients could have a major public health impact.
One study limitation is that baseline interviews are conducted 5 months after diagnosis.
Treatments subsequent to the first course of treatment may affect responses, and some
factors may have changed during this interval. Recall bias may also influence the results.
Detailed household composition information (e.g. number of children, wage earners) was
not collected, which limits our ability to interpret findings for this determinant. We could
not calculate poverty indices based on household size and income because we only collect
information on income categories.
Several factors known to impact timeliness of care were not captured in our study. We did
not have information on the healthcare facility where the women received care (e.g. urban/
rural location, type). A greater number of comorbidities is associated with increased
treatment delay (14, 15, 17) and African American race(14, 17), but was not assessed in our
analysis. Finally, we did not collect information from participants about their interaction
with providers. African American women are less trusting of their cancer treatment
team(58). Providers also communicate differently with African American and White
patients(59).
In conclusion, we found that the determinants of treatment delay vary by race, a finding that
may help explain the conflicting literature on racial disparities. Further investigation is
needed to determine the clinical relevance of the determinants we identified. Younger
African American women may need additional support to ensure timely care comparable to
White women. Our findings support targeting specific populations when identifying and
addressing determinants of treatment delay.
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Table 3
Association of selected characteristics with treatment delays of >30 days in the study population
Odds Ratio (95% CI)
Characteristic Crude Model Fully Adjusted Model
Household size
1 1.00 (ref) 1.00 (ref)
2 1.89 (1.22–2.94)* 2.08(1.19–3.63)*
3 1.48 (0.85–2.58) 1.61(0.86–3.02)
4 1.18 (0.64–2.20) 1.30(0.64–2.68)
>4 0.79 (0.37–1.66) 0.87(0.38–2.01)
Lost job due to diagnosis
No 1.00 (ref) 1.00 (ref)
Yes 2.04 (0.94–4.42) 2.19(1.00–4.81)
First treatment/reconstruction
Breast conserving surgery 1.00 (ref) 1.00 (ref)
Mastectomy without reconstruction 1.30 (0.82–2.05) 1.45 (0.84–2.50)
Mastectomy with reconstruction 5.82 (3.16–10.73)* 6.18 (3.27–11.68)*
Neoadjuvant therapy 1.68 (1.05–2.71)** 2.06 (1.16–3.66)**
CI: confidence interval; Crude Model: adjusted for race, age, race x age; Fully Adjusted models: Household size additionally adjusted for marital
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Table 4
Association of race with treatment delays of >30 days in the study population
Odds Ratio (95% CI)
Race, Age range Crude Model Model 1 Model 2 Fully Adjusted Model
White, 20–39 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref)
African American, 20–39 1.75 (0.66–4.66) 1.52 (0.55–4.15) 1.91 (0.68–5.37) 3.34(1.07–10.38)**
White, 40–49 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref)
African American, 40–49 2.61 (1.50–4.56)* 2.45 (1.37–4.39)* 2.56 (1.42–4.64)* 3.40(1.76–6.54)*
White, 50–64 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref)
African American, 50–64 0.79 (0.46–1.36) 0.84 (0.47–1.52) 0.84 (0.46–1.52) 0.95 (0.51–1.77)
White, 65–74 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref)
African American, 65–74 1.27 (0.54–2.94) 1.38 (0.54–3.53) 1.34 (0.51–3.51) 1.45 (0.54–3.91)
White, 20–39 0.60 (0.28–1.29) 0.64 (0.29–1.42) 0.57 (0.25–1.30) 0.32(0.13–0.80)**
White, 40–49 0.47 (0.26–0.82)* 0.52 (0.29–0.93)** 0.49 (0.27–0.89)** 0.38(0.20–0.73)*
White, 50–64 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref)
White, 65–74 0.64 (0.33–1.24) 0.81 (0.37–1.78) 0.77 (0.34–1.75) 0.87(0.38–2.02)
African American, 20–39 1.32 (0.59–2.97) 1.15 (0.50–2.67) 1.30 (0.55–3.08) 1.12(0.44–2.86)
African American, 40–49 1.54 (0.90–2.63) 1.49 (0.85–2.62) 1.48 (0.84–2.63) 1.37(0.75–2.48)
African American, 50–64 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref)
African American, 65–74 1.03 (0.48–2.20) 1.32 (0.54–3.20) 1.23 (0.50–3.03) 1.33(0.52–3.40)
CI: confidence interval; Crude Model: adjusted for age, race x age; Model 1: adjusted for age, race x age, income, insurance; Model 2: adjusted
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